Dr. Nameer Haider – Combining Minimally Invasive Surgery, Neuromodulation, and Regenerative Medicine
May 8, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) In a recent episode of The Back Doctors Podcast, SynerFuse® Chief Innovation Officer Dr. Nameer Haider shared with host Dr. Michael Johnson various minimally invasive surgical procedures that he utilizes, as well as combining these surgeries with neuromodulation and regenerative medicine.
BizTalk Weekly Podcast with Guest Justin Zenanko
May 4, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) Justin Zenanko, founder of SynerFuse®, discusses his entrepreneurial journey with BizTalk Weekly podcast host Gregg Johnson of Focal Point Business Coaching.
SynerFuse adds 3 physicians to board of medical advisors
April 23, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) SynerFuse added three pain management physicians to its board of medical advisors, according to an April 23 news release shared with Becker’s.
The Jack Tomczak Show: SynerFuse® and SynerFuse® Motorsports
April 7, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) In this segment from the Jack Tomczak Show on WWTC 1280AM The Patriot in the Twin Cities, SynerFuse® CEO Justin Zenanko discusses the company and its motorsports sponsorship.
Listen below.
Innovation in Compliance: Dr. Rohan Lall: Innovation, Clinical Evidence, and Compliance in Electrifying Spine Surgery
April 7, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) In this episode of the Innovation in Compliance podcast, host Tom Fox visits with SynerFuse® Chief Medical Officer, Rohan Lall, M.D., about innovation in spine surgery and the compliance infrastructure needed to support it.
Dr. Thomas Lee named SynerFuse VP of strategy
April 2, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) Neurosurgeon Thomas Lee, MD, was named vice president of strategy at SynerFuse.
SynerFuse® Announces VP of Strategy: Thomas T. Lee, M.D., FAANS, MBA
April 2, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) Dr. Lee is a renowned talent in the fields of both neurosurgery and finance.
SynerFuse names Dr. Adeel Khan as vice president of regenerative medicine
March 24, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) SynerFuse named Adeel Khan, MD, as vice president of regenerative medicine… Dr. Khan is a physician and regenerative medicine expert, and he was one of the first researchers in Canada to publish on intraosseous PRP.
SynerFuse® Announces VP of Regenerative Medicine: Dr Adeel Khan
March 24, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) SynerFuse®, Inc., a Minnesota-based medical device company, today announced the appointment of Adeel Khan, M.D., as vice president of regenerative medicine.
Spinal Fusion and Pain Management
March 4, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) In this episode of the Avoiding the Addiction Affliction podcast, hosted by Mike McGowan, SynerFuse® Chief Medical Officer Rohan Lall, M.D., discusses our groundbreaking new procedure being developed to help people with chronic lower back pain.
Spine device company names new chief innovation officer
February 26, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) SynerFuse, a spinal fusion medical device company, has appointed Nameer Haider, MD, as chief innovation officer.
Using Private Capital to Preserve Control
February 11, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) In this episode of the Medsider podcast, host Scott Nelson and SynerFuse® President & CEO Justin Zenanko discussed how to validate your idea before committing millions to custom device development, what contract manufacturers need to execute effectively for early-stage medtech companies, how investment banks structure private raises to preserve founder control, and more.
SynerFuse® Announces Primary Sponsorship of Jake Bollman and Nitro Motorsports for the ARCA Menards Series General Tire 200 at Daytona
February 10, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) SynerFuse® today announced a primary sponsorship of Nitro Motorsports driver Jake Bollman and the No. 20 entry for the ARCA Menards Series General Tire 200 at Daytona International Speedway, scheduled for Saturday, February 14, 2026.
When Chronic Spine Pain Becomes Surgical: Advances in Modern Spine Care
February 2, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) In this episode of MedInsights Unleashed, the discussion focuses on advanced chronic spine pain and when surgery becomes part of the care pathway. Dr. Rohan R. Lall, neurosurgeon at M Health Fairview University of Minnesota Medical Center, shares clinical perspective on evolving surgical approaches for patients with severe degeneration, instability, and chronic nerve-related pain.
Dr. Rohan Lall -- Rewriting Pain Care: A Neurosurgeon's Mission to Revolutionize Pain Management
January 14, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) In this episode of the Clinical Research Coach podcast, host Leanne Woehlke interviews Dr. Rohan Lall, who brings a rare dual perspective as a practicing physician and clinical research leader.
The Latest in Back Pain Treatment with Dr. Rohan Lall
January 7, 2026
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) In this podcast, host Michael Levin-Epstein chats with Dr. Rohan Lall, Neurosurgeon and Medical Director of Community Neurosurgery for M Health Fairview. Together, they discuss Rohan’s involvement in a key clinical trial for back pain treatment; what the SynerFuse e-TLIF procedure is and how patients and surgeons prep for it; and more.
Reinventing Back Surgery: Dr. Steve Falowski on SynerFuse’s Breakthrough in Chronic Pain Treatment
December 16, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) In this episode of Liftoff, host Keith Newman talks with Dr. Steven M. Falowski, MD, FAANS — Director of Functional Neurosurgery and Strategic Advisor at SynerFuse®, the company pioneering a transformational approach to spinal surgery.
SynerFuse ULE: Pioneering the Future of Spine Surgery
December 1, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) In this episode of the Surgical Pioneering Podcast, Dr. Reza Lankarani provides a sharp, insightful review of the pioneering work that SynerFuse® Chief Medical Officer Rohan Lall, M.D., is doing and of the company's e-TLIF™procedure.
Dr. Steven Falowski – SynerFuse®
November 24, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) On The Back Doctors podcast hosted by Dr. Michael Johnson, Dr. Steven Falowski, SynerFuse® strategic advisor, shares an exciting new development in spine surgery that combines the two therapy modalities of spinal fusion and neuromodulation into a single solution implanted simultaneously at the point of a spinal fusion procedure.
SynerFuse® Announces Chief Technology Officer | Michael Park, M.D., Ph.D.
June 10, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) SynerFuse® Inc., a Minnesota-based medical device company, today announced the appointment of Michael Park, M.D., Ph.D., as the company’s chief technology officer. Dr. Park is a former principal investigator for the SynerFuse® proof-of-concept study and primary inventor of SynerFuse® technology.
SynerFuse taps neurosurgeon as chief technology officer
June 10, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) Medical device company SynerFuse has tapped neurosurgeon Michael Park, MD, PhD, as its chief technology officer.
SynerFuse Takes The Spotlight As A Sponsor, Exhibitor & Honoree At Health 2.0 Conference 2025
May 22, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Las Vegas, Nev.) SynerFuse, Inc. made a significant impact as a Silver Sponsor and Exhibitor at the recently concluded Health 2.0 Conference, held from March 4–6, 2025, at the Luxor Hotel & Casino in Las Vegas.
SynerFuse® and its innovative approach to spine surgery: better outcomes, improved lives
May 1, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Scottsdale, Ariz.) Capital Fit CEO Daniel Barnard recently had the opportunity to talk with Justin Zenanko, President & CEO of SynerFuse®, which is a cutting-edge, Minnesota-based medical device company innovating the spine industry with its integrated approach to spinal fusion and chronic low back & leg pain.
Minnesota-Developed SynerFuse Implant for Chronic Back Pain Advances Toward FDA Approval
April 8, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) A groundbreaking surgical implant developed in Minnesota for treating chronic back pain has reached a significant milestone on its path to FDA approval, offering hope to millions suffering from debilitating spinal conditions.
Surgery for opioid-free relief from back pain is one step closer to FDA approval
April 7, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) Synerfuse®, the world's first double infusion implant, combines traditional spine surgery with nerve stimulators. It was developed by specialists from the University of Minnesota and M Health Fairview.
Patient up and walking after groundbreaking spinal surgery by South Bend doctor - Part 2
April 4, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(South Bend, Ind.) A groundbreaking spinal surgery brings a man a second chance to enjoy his life.
Patient up and walking after groundbreaking spinal surgery by South Bend doctor - Part 1
April 4, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(South Bend, Ind.) A groundbreaking spinal surgery brings a man a second chance to enjoy his life.
Honoring Excellence | A Chat with Justin Zenanko
March 25, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Las Vegas, Nev.) Justin Zenanko, CEO & Co-Founder of SynerFuse®, Inc., reflects on being awarded the "Visionaries Award" at the Health 2.0 Conference in Las Vegas. Held at the Luxor Hotel & Casino, Las Vegas, USA, from March 4-6, 2025, the event celebrated global leaders and innovators.
SynerFuse® and Velentium Medical to Scale Innovative e-TLIF™ Implant Procedure After Successful Proof-of-Concept
March 24, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) Next-generation therapy integrates neuromodulation with spinal fusion to improve outcomes and reduce opioid reliance for over 500,000 spinal surgery patients annually in the U.S.
SynerFuse® partners with Velentium Medical
March 21, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) SynerFuse® is partnering with Velentium Medical to scale the SynerFuse® e-TLIF implant, according to a March 21 news release.
SynerFuse® & Velentium Medical Partnering to Scale Integrated Spinal Fusion & Direct Nerve Stimulation Procedure
March 21, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) SynerFuse® and Velentium Medical announced plans to scale their patented SynerFuse® e-TLIF procedure implant device following the completion of their proof-of-concept study.
SynerFuse® & Velentium Medical Announce Development and Manufacturing Partnership
March 21, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) SynerFuse® and its partner, Velentium Medical, today announced plans to scale the patented SynerFuse® e-TLIF procedure implant device. Earlier this month SynerFuse® announced the successful completion of its 15-patient proof-of-concept study to evaluate the safety and tolerability of the novel Electric Transforaminal Lumbar Interbody Fusion (e-TLIF) procedure.
SynerFuse® Study Achieves Milestone in Chronic Pain Treatment
March 3, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) SynerFuse® and its collaborators have successfully finished an essential proof-of-concept study aimed at determining the safety and tolerability of the Electric Transforaminal Lumbar Interbody Fusion (e-TLIF™) procedure. This innovative technique merges traditional spinal fusion with the direct stimulation of nerves, intended specifically for those battling chronic lower back pain.
SynerFuse® completes 1st study for electric transforaminal lumbar interbody fusion
March 3, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) SynerFuse®, in partnership with the Minneapolis-based University of Minnesota, South Bend (Ind.) Orthopaedics and RQM+, has completed the first proof-of-concept study of its electric transforaminal lumbar interbody fusion procedure.
SynerFuse® Completes Proof-of-Concept Study
March 3, 2025
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
SynerFuse® and its collaborators at the University of Minnesota, South Bend Orthopaedics, and RQM+ today announced the completion of the SynerFuse® proof-of-concept study to evaluate the safety and tolerability of the novel Electric Transforaminal Lumbar Interbody Fusion (e-TLIF) procedure integrating spinal fusion with direct nerve stimulation, which is designed to treat chronic lower-back pain (cLBP) and neuropathic leg pain.
Justin Zenanko – SynerFuse® and New e-TLIF™ Procedure
November 19, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) The patented SynerFuse® procedure, Electric Transforaminal Lumbar Interbody Fusion (e-TLIF™), combines fusion with direct nerve stimulation to address chronic low back and leg pain that is unaddressed in traditional spinal fusion surgery. SynerFuse® CEO Justin Zenanko and The Back Doctors podcast host Dr. Michael Johnson discuss it.
Beyond Opioids: Justin Zenanko’s Vision for Spinal Fusion and Chronic Pain Relief
November 1, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) In this episode of Med Tech Talks, host Robert Klupacs is joined by Justin Zenanko, co-founder, CEO and president of SynerFuse®, a medical device company based in the United States developing an innovative solution to reduce chronic back pain and improve patient quality of life.
New medical technology is helping remove chronic back pain
October 10, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Duluth, Minn.) A Duluthian man went from barely able to walk to now moving around pain-free thanks to this new innovative medical technology. SynerFuse® is a company made of specialists from the University of Minnesota and the Fairview Health system. They are working towards better and more regular outcomes with spine surgeries.
From CPA to Innovator in Medical Device Technology with Justin Zenanko
September 24, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) In this episode, The Deal Scout podcast host Josh Wilson converses with SynerFuse® CEO Justin Zenanko, "a remarkable guest whose journey from a certified public accountant (CPA) to a key player in the medical device industry is nothing short of inspiring... Justin’s transition from a CPA to raising capital for groundbreaking medical technologies is a testament to the power of adaptability and passion."
Hard Things Are Worth Doing: Circuit Breakers with Justin Zenanko of SynerFuse®
September 9, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) Circuit Breakers is an interview series by Steve Semler of FocalPoint/LearningSim with business leaders in or supporting the tech sector. In the interview, Semler explored how SynerFuse®, as a leader in the technology business, “breaks the circuit” of the routine and stays innovative.
An Innovative Medical Device Tackling Back Pain and Combating the Opioid Crisis
September 9, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) In this episode of the "Capitalist Culture" podcast, SynerFuse CEO Justin Zenanko discusses valuable lessons and innovative ideas that host Kip Knippel says are "sure to resonate with investment groups and growth-stage business owners."
SynerFuse® Combines Fusion and Stimulation to Treat Back Pain
August 21, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) ORTHOWORLD spoke with SynerFuse® CEO Justin Zenanko about the company's technology and next steps.
What Is the End Goal?
July 24, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) Justin Zenanko CEO & Co-Founder of Synerfuse® covers some key points in bringing innovation to the healthcare space in this episode.
Combating the Opioid Crisis with Technology with Justin Zenanko CEO of SynerFuse®
July 16, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse® makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse®.
(Eden Prairie, Minn.) Justin Zenanko, CEO and co-founder of SynerFuse® discusses a groundbreaking technique combining spinal fusion and direct nerve stimulation to treat chronic low back pain, aiming to eliminate the need for postoperative opioids.
SynerFuse® names spine surgeon medical advisory board chair, vice chair
May 15, 2024
(Eden Prairie, Minn.) Steven Falowski, MD, was named chair of the SynerFuse® medical advisory board, and Deepak Reddy, MD was named vice chair.
SynerFuse® Announces Medical Advisory Board Appointments
May 15, 2024
(Eden Prairie, Minn.) SynerFuse® today announced the appointment of Steven Falowski, M.D., FAANS as chair of the company’s Medical Advisory Board and Deepak Reddy, M.D. as vice chair.
6 spine surgeon moves in January
February 1, 2024
(Eden Prairie, Minn.) Here are six spine surgeons who moved to new practices or added to their titles in January.
3 spine, orthopedic leadership shake-ups in 1 week
January 8, 2024
(Eden Prairie, Minn.) Here are three C-suite leadership moves in the spine and orthopedic space Becker's has reported on since Jan. 3.
SynerFuse® appoints Rohan Lall as chief medical officer
January 8, 2024
(Eden Prairie, Minn.) SynerFuse® has announced the appointment of Rohan Lall (M Health Fairview Neurosurgery, Princeton, USA) as the company’s chief medical officer. The appointment was effective on 2 January 2024.
SynerFuse® Appoints Dr. Rohan Lall Chief Medical Officer
January 3, 2024
(Eden Prairie, Minn.) SynerFuse today announced the appointment of Rohan Lall, M.D., as the company’s chief medical officer. Dr. Lall co-developed the patented Electric Transforaminal Lumbar Interbody Fusion (e-TLIF) SynerFuse procedure, which combines fusion with direct nerve stimulation to address chronic low back and leg pain that is unaddressed in traditional spinal fusion surgery.
Dr. Rohan Lall named chief medical officer of SynerFuse®
January 3, 2024
(Eden Prairie, Minn.) Rohan Lall, MD, was named chief medical officer of SynerFuse®. Dr. Lall helped develop the company's Electric Transforaminal Lumbar Interbody Fusion procedure, according to a Jan. 3 news release shared with Becker's.
For media inquiries, contact Kent Kaiser at kent@ainsleyshea.com
